all report title image
  • Published On : May 2022
  • Code : CMI5022
  • Industry : Pharmaceutical
  • Pages : 206
  • Formats :

Conventional drug delivery approaches have issues pertaining to repeated dosing and systemic toxicity. Hence, new drug delivery systems are now developed for overcoming these disadvantages and optimizing the therapeutic benefits of the drugs. Hydrogels have a wide range of biomedical applications other than drug delivery such as manufacturing contact lenses, wound dressings, and tissue engineering. The mechanism of drug delivery by using hydrogel involves diffusion-based drug release from the hydrogel mesh or pores filled with water. This reservoir delivery system ensures time-independent and constant drug release. Different hydrogel products are administered by various routes of administration such as peroral, rectal, ocular, and transdermal among others. The hydrogel systems have several therapeutic applications such as for treating inflammatory diseases, cardiac illness & cancer, and diabetic foot ulcer among others.   

The global hydrogel-based drug delivery system market is estimated to be valued at US$ 4,785.4 million in 2022 and is expected to exhibit a CAGR of 6.9% during the forecast period (2022-2030).

Figure 1. Global Hydrogel-Based Drug Delivery System Market in Terms of Value (US$ million), By Region, 2022

Hydrogel-Based Drug Delivery System  | Coherent Market Insights

Increasing application of hydrogel-based drug delivery systems to treat various disorders such as metabolic syndrome is expected to drive the global hydrogel-based drug delivery system market growth during forecast period.

Researchers across the world are creating new drug delivery models for efficient drug delivery which is driving the growth of the hydrogel-based drug delivery system market over the forecast period. For instance, in 2021, researchers from Marine College, Shandong University, China, and Universidad de Talca, Chile demonstrated that the use of hydrogel-based controlled release system increased the therapeutic efficacy in various components of the metabolic syndrome. The study concluded that these hydrogel systems had various advantages such as sustained pharmacological release which ensured a safe route of administration of drug and avoided the need for repeated doses.

CMI table icon

Hydrogel-Based Drug Delivery System Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 4,785.4 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 6.9% 2030 Value Projection: US$ 8,187.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Source: Natural, Synthetic, Hybrid
  • By Route of Delivery: Oral Cavity, Subcutaneous, Topical, Others
Companies covered:

Johnson & Johnson, Bausch & Lomb, Ocular Therapeutix, Inc, Tolmar Pharmaceuticals, Inc., Ashland, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Micropore Technologies, Neurelis, Inc., and ProLynx Inc.

Growth Drivers:
  • Increasing application of hydrogel-based drug delivery systems to treat various disorders such as metabolic syndrome
  • Increasing approval of new hydrogel-based products 
Restraints & Challenges:
  • Limitations such as slow responsiveness and possibility of drug inactivation associated with hydrogel-based drug delivery system

Figure 2. Global Hydrogel-Based Drug Delivery System Market Share in Terms of Value (US$ Mn), By Route of Delivery, 2022

Hydrogel-Based Drug Delivery System  | Coherent Market Insights

The increasing approval of new hydrogel-based products is expected to drive the market growth over the forecast period.

New products based on hydrogel drug delivery systems are receiving marketing authorization which can be further contributing to the market growth. For instance, in April 2019, the U.S. Food and Drug Administration approved Plenity manufactured by Gelesis a biotechnology company for the treatment of obesity. Plenity is a non-systemic, oral formulation made up of superabsorbent hydrogel which is used for weight management in adults. The capsule works by inducing a feeling of fullness so that individuals eat less and eventually aid in losing weight. Hence, such approvals for drugs based on hydrogel technology are expected to drive the market growth over the forecast period.

Global Hydrogel-Based Drug Delivery System Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization declared COVID-19 a pandemic on March 11, 2020. According to the Coronavirus Disease (COVID-19), Weekly Epidemiological Update by the World Health Organization, over 409 million cases and 5.8 million deaths due to coronavirus disease (COVID-19) were reported up till 13th, February 2022 across the globe.

The Covid-19 pandemic has made the need for understanding biocompatible polymers as support material for controlled drug delivery especially for organohydrogels. Several studies are conducted for characterization of novel organohydrogel as a natural drug carrier or release material. For instance, in January 2021, researchers synthesized various new polymeric materials such as hydrogels, organohydrogels, and gels for investigating their use as drug release systems. The study concluded that organohydrogels can be used as drug carrier and controlled drug release materials. Hence, the high R&D activities in the pandemic for understanding the potential use of hydrogels in drug delivery is positively impacting the market growth over the forecast period.

Global Hydrogel-Based Drug Delivery System Market: Restraint

The limitations associated with hydrogel-based drug delivery system is likely to hamper the market growth. For instance, the common limitations of hydrogels as drug delivery systems are non-biodegradable properties of some hydrogels, slow responsiveness, possibility of drug inactivation, and rapid release of drug owing to hydrogel swelling and bursting. Hence, overcoming these challenges by different approaches is required for ensuring it as efficient drug delivery method.

Key Players                                                               

Major players operating in the global hydrogel-based drug delivery system market include Johnson & Johnson, Bausch & Lomb, Ocular Therapeutix, Inc, Tolmar Pharmaceuticals, Inc., Ashland, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Micropore Technologies, Neurelis, Inc., and ProLynx Inc.

Hydrogels are referred as natural or synthetic polymer materials that exhibit very versatile physical and biological properties. These polymers were first used as biological materials in 1960. Based on the source, the hydrogel can be obtained from natural sources or are synthetic in origin. The natural hydrogel include silk fibroin, alginate, chitosan, collagen, and hyaluronic acid. However, these natural hydrogels have few limitations such as they involve batch-to-batch variation leading to inconsistency in the product. Hence, they are often combined with synthetic hydrogels for creating a composite polymer.

Hydrogels are often used as drug delivery systems owing to its high compatibility with living tissues and property to preserve embedded proteins. Hydrogel-based drug delivery system acts as controlled drug delivery systems for delivering a certain drug such as antibiotics for a predefined duration of time. The other applications of hydrogel in medical sciences include replacement, restoration of anatomic structures, filtering wastewater, making contact lenses, and as pH sensors among others.

Market Dynamics

The growing research and development activities for using hydrogel-based drug delivery system for treating various injuries such as spinal cord injuries are contributing to the growth of hydrogel-based drug delivery system market. For instance, in January 2021, University of Arkansas biomedical engineering researcher was awarded a grant of US$100,000 from the PhRMA Foundation, an organisation that offers research grants; for developing the hydrogel-based drug delivery method for treating spinal cord injuries. The process involves embedding the stem cells in the matrix hydrogels, which facilitates better cell survival and hence can perform regenerative action for a longer duration.

 Key features of the study:

  • This report provides an in-depth analysis of the global hydrogel-based drug delivery system market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hydrogel-based drug delivery system market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
  • Key companies covered as a part of this study include Johnson & Johnson, Bausch & Lomb, Ocular Therapeutix, Inc, Tolmar Pharmaceuticals, Inc., Ashland, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Micropore Technologies, Neurelis, Inc., and ProLynx Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global hydrogel-based drug delivery system market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global hydrogel-based drug delivery system market

Detailed Segmentation:

  • Global Hydrogel-Based Drug Delivery System Market, By Source
    • Natural
      • Synthetic
      • Hybrid
  • Global Hydrogel-Based Drug Delivery System Market, By Route of Delivery
    • Oral Cavity
    • Subcutaneous
    • Topical
    • Others
  • Global Hydrogel-Based Drug Delivery System Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Johnson & Johnson**
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Bausch & Lomb
    • Ocular Therapeutix, Inc
    • Tolmar Pharmaceuticals, Inc.
    • Ashland
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Micropore Technologies
    • Neurelis, Inc.
    • ProLynx Inc

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The market is estimated to be valued at US$ 4,785.4 million in 2022 and is expected to exhibit a CAGR of 6.9% between 2022 and 2030.
Factors such as increasing approval of new hydrogel-based products is expected to drive the market growth during the forecast period.
Oral cavity is expected to hold a major market share during the forecast period in the route of delivery segment.
The major factor hampering growth of the market include limitations such as slow responsiveness and possibility of drug inactivation associated with hydrogel-based drug delivery system.
Major players operating in the market include Johnson & Johnson, Bausch & Lomb, Ocular Therapeutix, Inc, Tolmar Pharmaceuticals, Inc., Ashland, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Micropore Technologies, Neurelis, Inc., and ProLynx Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo